ClinicalTrials.gg
RecruitingNCT07912385Updated Nov 3, 2026

Observational Study of the LambdaGuide System for Measurement of Observable Genitourinary Anatomy During Cystoscopic Procedures in Men

An observational study in Genitourinary Anatomy, sponsored by Lambda Surgical, Inc. Recruiting at 1 site in United States. Open to male participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Lambda Surgical, Inc · Observational

Updated Nov 3, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
10
Ages
22 Years and older
Sex
Male
01

Study summary

This prospective clinical study will evaluate the feasibility, performance, and safety of the LambdaGuide System for obtaining point-to-point measurements of observable genitourinary anatomy during cystoscopic procedures in adult men. The system is intended to provide measurements of anatomical structures visible during cystoscopy without influencing clinical diagnosis or treatment decisions.

The study will assess successful calibration, spatial capture, measurement point selection, and completion of point-to-point measurements. Device usability, procedural workflow effects, and adverse events will also be evaluated. Optional comparisons with known-dimension references may be performed for descriptive purposes.

LambdaGuide measurements will not be used to guide or modify clinical care.

Read the detailed description

This is a prospective, observational clinical study designed to evaluate the feasibility, functional performance, usability, and safety of the LambdaGuide System during cystoscopic procedures in adult male participants aged 22 years and older.

The LambdaGuide System is an investigational optical measurement system that integrates with a compatible cystoscope. It uses an optical camera module, calibration process, spatial capture, and software-based point selection to obtain point-to-point measurements of anatomical structures visible within the urinary tract.

Participants may include men undergoing non-emergency cystoscopic procedures and, where specifically authorized under the approved research protocol, healthy adult male volunteers. Study participation involves use of the LambdaGuide System during cystoscopic visualization. For patients undergoing clinically indicated cystoscopy, the investigational measurements are performed alongside standard clinical care. LambdaGuide measurements will not be used to make diagnostic or therapeutic decisions, select treatment, or modify standard clinical care.

During the procedure, qualified clinicians will set up the LambdaGuide System, perform calibration using an approved calibration target, and attempt measurements of observable urinary anatomy. Potential measurement targets include anatomical openings or narrowing, urethral strictures, distances between anatomical landmarks, urinary tract lesions, stones, foreign bodies, and implant-related structures.

For each measurement attempt, the study will document the ability to obtain spatial information, select two valid measurement points, and display a point-to-point measurement. The primary performance endpoint is procedure-level clinical measurement feasibility, defined as obtaining at least one successful point-to-point measurement during an evaluable procedure.

Additional assessments include calibration success, camera deployment and image display, spatial capture success, measurement completion, calibration and measurement time, procedural interference, and clinician-reported usability. Optional observational comparisons with known-dimension references may be performed. These comparisons are descriptive and are not intended to establish measurement accuracy.

Safety will be evaluated through documentation of adverse events, including their severity, seriousness, and relationship to the investigational device or study procedures. Device deficiencies and malfunctions will also be recorded. Participants will undergo post-procedure safety assessment and follow-up approximately 30 days after the procedure, within a permitted window of ±5 days.

The study is intended to characterize the LambdaGuide System's ability to obtain measurements of visible genitourinary anatomy in a clinical environment and to collect performance, usability, and safety data to support further device evaluation.

02

Conditions studied

  • Genitourinary Anatomy

Browse trials for

Keywords

  • Genitourinary Anatomy
  • Urologic Endoscopy
  • Cystoscopy
  • Anatomical Measurement
  • Point-to-Point Measurement
  • Optical Measurement
  • Endoscopic Imaging
  • Urethral Stricture
03

In context

Urethral Stricture

72 studies on the registry are indexed under Urethral Stricture; 25 are open to participants now.

This study's planned enrollment of 10 is below the median of 175 across 11 observational studies indexed under Urethral Stricture.

Browse Urethral Stricture studies →

Lead sponsor

This is the only study on the registry with Lambda Surgical, Inc as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

No additional description beyond Eligibility Criteria. Subjects should be able to travel to a study site.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male subject (22 years of age or older).
  2. Subject who undergoes a non-emergency cystoscopic procedure, or a healthy volunteer.
  3. Able and willing to provide before study participation.
  4. Procedure is expected to provide visualization of observable urinary anatomy suitable for an attempted measurement.
  5. Investigator determines that study participation is appropriate and will not interfere with standard clinical care.
  6. Investigator determines, based on medical history and physical examination, that the subject is medically appropriate to undergo the study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Participation is expected to interfere with or materially delay standard clinical care.
  2. Known clinical condition or procedural circumstance that, in the investigator's judgment, makes study participation inappropriate.
  3. Inability to provide .
  4. Inability to use the required compatible cystoscope or approved study configuration.
  5. Known allergy or to the local anesthetic planned for the cystoscopic procedure.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Clinical measurement feasibility

    Clinical measurement feasibility, assessed as a procedure-level pass/fail outcome. An evaluable procedure passes if at least one successful point-to-point measurement is obtained.

    Time frame: Procedure duration

  2. Primary safety endpoint

    Incidence, severity, seriousness, and relatedness of device-related, procedure-related, and other adverse events.

    Time frame: From procedure date to 30 days after (+/-5 days)

Secondary outcomes

  1. Calibration success

    Calibration success

    Time frame: During Procedure

  2. Camera deployment and expected image display

    Camera deployment and expected image display

    Time frame: During Procedure

  3. Spatial capture success

    Spatial capture success

    Time frame: During Procedure

  4. Valid point-selection success

    Valid point-selection success

    Time frame: During Procedure

  5. Successful measurement completion

    Successful measurement completion

    Time frame: During Procedure

  6. Calibration and measurement time

    Calibration and measurement time (descriptive only)

    Time frame: During Procedure

  7. Procedure interference

    Procedure interference

    Time frame: During Procedure

  8. User acceptance

    User acceptance - based on Investigator Questionnaire

    Time frame: During Procedure

  9. Observational comparative measurements (

    Observational comparative measurements (descriptive only)

    Time frame: During Procedure

07

Study locations

1 of 1 sites recruiting
  • PINE (Prostate Institution of New England)
    Boston, Massachusetts 02111, United States
    Recruiting
    • Alethia Chan · Contactchanalethia@gmail.com · 857-800-2305
    • Louis Liou, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07912385
Lead sponsor
Lambda Surgical, Inc
Responsible party
Sponsor
First posted
Nov 3, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Sarah Lapp
Contact
sarah@lambdasurgical.com
678-231-0685
Louis Liou, MD, PhD
principal investigator · PINE - Prostate Institution of New England

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion